Alivus Life Sciences delivers 12% revenue growth
EBITDA margins expand to 31.3%
EBITDA margins expand to 31.3%
The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
This certification will open new markets for the Kwality Pharma
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
Mesalazine is used to treat inflammatory bowel disease
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
Subscribe To Our Newsletter & Stay Updated